C4 Therapeutics Inc (CCCC) Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy C4 Therapeutics Inc (CCCC) following the 2026 Q2 hedge fund 13F filings?

As of today, CCCC has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), CCCC gained -9.2% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

C4 Therapeutics Inc (CCCC)

120 + Investors. Track Smart Money conviction in CCCC. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — CCCC

Based on 121 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q

For 2 consecutive quarters, more hedge funds added CCCC than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

121 hedge funds hold CCCC right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

📶

Steady growth — +6% more funds vs a year ago

fund count last 6Q

+7 new funds entered over the past year (+6% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction. The peak was reached in just 4 quarters from the low — a sharp move.

🟢

More buyers than sellers — 62% buying

73 buying45 selling

Last quarter: 73 funds were net buyers (32 opened a brand new position + 41 added to an existing one). Only 45 were sellers (33 trimmed + 12 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+10 vs last Q)

new funds entering per quarter

Funds opening a new CCCC position: 25 → 24 → 22 → 32. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔒

45% of holders stayed for 2+ years

■ 45% conviction (2yr+) ■ 23% medium ■ 32% new

54 out of 121 hedge funds have held CCCC for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💰

Value +38% but shares only +3% — price-driven

Value

+38%

+3%

Last quarter: the total dollar value of institutional holdings rose +38%, but actual share count only changed +3%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

📈

Growing discovery — still being found

27 → 25 → 24 → 22 → 32 new funds/Q

New funds entering each quarter: 25 → 24 → 22 → 32. A growing number of institutions are discovering CCCC each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

🏛️

Veteran-anchored — 55% veterans vs 34% newcomers

■ 55% veterans ■ 11% 1-2yr ■ 34% new

Entry-cohort mix of 127 holders: 70 (55%) are 2+ year veterans, 14 entered 1–2 years ago, and 43 (34%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

✅

Strong quality — 36% AUM from major funds

36% from top-100 AUM funds

29 of 121 holders rank in the top 100 by AUM, accounting for 36% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

3.9

out of 10

Low Exit Risk

Exit risk score 3.9/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	120	101	18.81%
13F Shares	83M	80M	3.22%
Total Value	$211M	$153M	38.27%
New Positions	31	22	+9
Increased Positions	39	44	-5
Closed Positions	12	19	-7
Reduced Positions	31	21	+10
Total Calls	4	3	33.33%
Total Puts	2	3	-33.33%
PUT/CALL Ratio	0.5	1.0	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

120

101

18.81%

13F Shares

83M

80M

3.22%

Total Value

$211M

$153M

38.27%

New Positions

Increased Positions

-5

Closed Positions

-7

Reduced Positions

+10

Total Calls

33.33%

Total Puts

-33.33%

PUT/CALL Ratio

0.5

1.0

Bullish

Institutional Holders (2026 Q2)

120 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CCCC. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 CCCC holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Squadron Capital Management LLC	10.43%	7,200,000	$33.6M
2	Lynx1 Capital Management LP	6.74%	7,326,691	$34.2M
3	Bain Capital Life Sciences Investors, LLC	1.99%	7,171,910	$33.5M
4	Velan Capital Investment Management LP	1.62%	570,000	$2.7M
5	Silverarc Capital Management, LLC	1.47%	3,032,060	$14.2M
6	HighVista Strategies LLC	1.44%	1,348,136	$6.3M
7	Ikarian Capital, LLC	1.22%	2,433,000	$11.4M
8	Patient Square Capital LP	1.16%	1,608,815	$7.5M
9	Squadron Capital Management LLC	0.58%	400,000	$1.9M
10	Soleus Capital Management, L.P.	0.54%	3,377,981	$15.8M
11	Platinum Investment Management Ltd	0.44%	384,766	$1.8M
12	Stempoint Capital LP	0.42%	523,648	$2.4M
13	Ra Capital Management, L.P.	0.32%	8,000,000	$37.4M
14	Intrepid Family Office LLC	0.22%	65,000	$304K
15	Atom Investors LP	0.15%	364,351	$1.7M
16	Palumbo Wealth Management LLC	0.13%	132,417	$618K
17	Wasatch Advisors LP	0.11%	3,522,644	$16.5M
18	Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group	0.10%	85,000	$397K
19	Scientech Research LLC	0.08%	21,260	$99K
20	Headlands Technologies LLC	0.08%	153,972	$719K
21	ADAR1 Capital Management, LLC	0.06%	291,957	$1.4M
22	CV Advisors LLC	0.06%	65,000	$304K
23	Boothbay Fund Management, LLC	0.05%	736,331	$3.4M
24	Candriam S.C.A.	0.04%	1,796,937	$8.4M
25	Dynamic Technology Lab Private Ltd	0.03%	32,828	$153K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — C4 Therapeutics Inc (CCCC)

What does the Smart Money Trend signal show for CCCC?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added CCCC than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CCCC?

More buyers than sellers — 62% buying: Last quarter: 73 funds were net buyers (32 opened a brand new position + 41 added to an existing one). Only 45 were sellers (33 trimmed + 12 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for CCCC holders?

Strong quality — 36% AUM from major funds: 29 of 121 holders rank in the top 100 by AUM, accounting for 36% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held CCCC?

45% of holders stayed for 2+ years: 54 out of 121 hedge funds have held CCCC for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy C4 Therapeutics Inc (CCCC) following the 2026 Q2 hedge fund 13F filings?

As of today, CCCC has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), CCCC has gained -9.2% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

C4 Therapeutics Inc (CCCC)

Smart Money Signals — CCCC

Buying streak — 2 quarters in a row

At the ownership peak (100% of max)

Steady growth — +6% more funds vs a year ago

More buyers than sellers — 62% buying

More new buyers each quarter (+10 vs last Q)

45% of holders stayed for 2+ years

Value +38% but shares only +3% — price-driven

Growing discovery — still being found

Veteran-anchored — 55% veterans vs 34% newcomers

Strong quality — 36% AUM from major funds

Institutional Sentiment Summary — CCCC

Hedge Fund Ownership: CCCC

Market Analysis: CCCC

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: CCCC

Is It Too Late to Buy C4 Therapeutics Inc (CCCC) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: CCCC

Statistics: CCCC

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — C4 Therapeutics Inc (CCCC)

Welcome to 13Foresight!